Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Two-in-One diabetes drug tested for better blood sugar control

NCT ID NCT06403761

Summary

This study tested a new investigational medicine called CagriSema, which combines two drugs, to see how it affects the body's insulin sensitivity in people with type 2 diabetes. 158 adults with type 2 diabetes who were already taking metformin received either CagriSema, one of its components, or a placebo for about 42 weeks. The main goal was to measure how well the body uses insulin to control blood sugar.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Profil Institut für Stoffwechselforschung GmbH

    Neuss, 41460, Germany

Conditions

Explore the condition pages connected to this study.